Blood-product usage in cardiac surgery

Joan Uehlinger, Louis M. Aledort

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Many patients undergo cardiac surgery with preexisting congenital and acquired coagulation defects. Almost all of these can be recognized and corrected preoperatively. CPB itself induces a variety of abnormalities of coagulation, affecting plasma proteins, platelets, and the fibrinolytic system. These abnormalities do not always cause clinically significant bleeding. When they do, logical laboratory assessment and blood-component usage can usually correct the defect. The use of blood products is associated with allergic, viral, and hemolytic risks. Exciting advances have been made in the use of synthetic alternatives to blood products. Both DDAVP and aprotinin seem promising in this respect, but more investigation is needed into the mechanisms of action and possible thrombotic complications of these drugs. In the future, anesthesiologists and surgeons may look forward to more safe and effective therapy of bleeding in cardiac surgical patients.

Original languageEnglish (US)
Pages (from-to)776-784
Number of pages9
JournalJournal of Cardiothoracic Anesthesia
Volume3
Issue number6
DOIs
StatePublished - 1989

Fingerprint

Thoracic Surgery
Hemorrhage
Deamino Arginine Vasopressin
Aprotinin
Blood Proteins
Blood Platelets
Pharmaceutical Preparations
Therapeutics
Anesthesiologists
Surgeons

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Blood-product usage in cardiac surgery. / Uehlinger, Joan; Aledort, Louis M.

In: Journal of Cardiothoracic Anesthesia, Vol. 3, No. 6, 1989, p. 776-784.

Research output: Contribution to journalArticle

Uehlinger, Joan ; Aledort, Louis M. / Blood-product usage in cardiac surgery. In: Journal of Cardiothoracic Anesthesia. 1989 ; Vol. 3, No. 6. pp. 776-784.
@article{549785cce7994c24b8686b852c778ce9,
title = "Blood-product usage in cardiac surgery",
abstract = "Many patients undergo cardiac surgery with preexisting congenital and acquired coagulation defects. Almost all of these can be recognized and corrected preoperatively. CPB itself induces a variety of abnormalities of coagulation, affecting plasma proteins, platelets, and the fibrinolytic system. These abnormalities do not always cause clinically significant bleeding. When they do, logical laboratory assessment and blood-component usage can usually correct the defect. The use of blood products is associated with allergic, viral, and hemolytic risks. Exciting advances have been made in the use of synthetic alternatives to blood products. Both DDAVP and aprotinin seem promising in this respect, but more investigation is needed into the mechanisms of action and possible thrombotic complications of these drugs. In the future, anesthesiologists and surgeons may look forward to more safe and effective therapy of bleeding in cardiac surgical patients.",
author = "Joan Uehlinger and Aledort, {Louis M.}",
year = "1989",
doi = "10.1016/S0888-6296(89)95320-9",
language = "English (US)",
volume = "3",
pages = "776--784",
journal = "Journal of Cardiothoracic and Vascular Anesthesia",
issn = "1053-0770",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Blood-product usage in cardiac surgery

AU - Uehlinger, Joan

AU - Aledort, Louis M.

PY - 1989

Y1 - 1989

N2 - Many patients undergo cardiac surgery with preexisting congenital and acquired coagulation defects. Almost all of these can be recognized and corrected preoperatively. CPB itself induces a variety of abnormalities of coagulation, affecting plasma proteins, platelets, and the fibrinolytic system. These abnormalities do not always cause clinically significant bleeding. When they do, logical laboratory assessment and blood-component usage can usually correct the defect. The use of blood products is associated with allergic, viral, and hemolytic risks. Exciting advances have been made in the use of synthetic alternatives to blood products. Both DDAVP and aprotinin seem promising in this respect, but more investigation is needed into the mechanisms of action and possible thrombotic complications of these drugs. In the future, anesthesiologists and surgeons may look forward to more safe and effective therapy of bleeding in cardiac surgical patients.

AB - Many patients undergo cardiac surgery with preexisting congenital and acquired coagulation defects. Almost all of these can be recognized and corrected preoperatively. CPB itself induces a variety of abnormalities of coagulation, affecting plasma proteins, platelets, and the fibrinolytic system. These abnormalities do not always cause clinically significant bleeding. When they do, logical laboratory assessment and blood-component usage can usually correct the defect. The use of blood products is associated with allergic, viral, and hemolytic risks. Exciting advances have been made in the use of synthetic alternatives to blood products. Both DDAVP and aprotinin seem promising in this respect, but more investigation is needed into the mechanisms of action and possible thrombotic complications of these drugs. In the future, anesthesiologists and surgeons may look forward to more safe and effective therapy of bleeding in cardiac surgical patients.

UR - http://www.scopus.com/inward/record.url?scp=0024829382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024829382&partnerID=8YFLogxK

U2 - 10.1016/S0888-6296(89)95320-9

DO - 10.1016/S0888-6296(89)95320-9

M3 - Article

VL - 3

SP - 776

EP - 784

JO - Journal of Cardiothoracic and Vascular Anesthesia

JF - Journal of Cardiothoracic and Vascular Anesthesia

SN - 1053-0770

IS - 6

ER -